Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
12:02pm, Tuesday, 17'th Feb 2026
Insights from Jeremy Grantham (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Jeremy Grantham (Trades, Portfolio) recently submitted the 13F filing for th
Mueller Industries Inc: A Key Focus in Mario Gabelli's Latest 13F Filing
05:05pm, Friday, 06'th Feb 2026
Insights into Mario Gabelli (Trades, Portfolio)'s Investment Moves in Q4 2025 Mario Gabelli (Trades, Portfolio) recently submitted the 13F filing for the fourt
Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
10:01am, Thursday, 13'th Nov 2025
Insights from Jeremy Grantham (Trades, Portfolio)'s Third Quarter 2025 13F Filing Jeremy Grantham (Trades, Portfolio) recently submitted the 13F filing for the
Sumitomo Mitsui Trust Group Inc. Buys 205 Shares of Verona Pharma PLC American Depositary Share $VRNA
04:18am, Saturday, 01'st Nov 2025
Sumitomo Mitsui Trust Group Inc. increased its stake in Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) by 4.6% during the second quarter, according to the company in its most recent 13F fi
Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on Monday
02:00am, Saturday, 01'st Nov 2025
Verona Pharma PLC American Depositary Share (NASDAQ: VRNA - Get Free Report) is anticipated to announce its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company
IFP Advisors Inc Acquires Shares of 547 Verona Pharma PLC American Depositary Share $VRNA
03:07am, Wednesday, 22'nd Oct 2025
IFP Advisors Inc acquired a new stake in Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutio
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
04:05pm, Monday, 06'th Oct 2025
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a de
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
04:05pm, Wednesday, 24'th Sep 2025
LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered i
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
06:00am, Tuesday, 16'th Sep 2025
Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
01:01pm, Tuesday, 12'th Aug 2025
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today
08:39am, Thursday, 31'st Jul 2025
Investing in index funds is a safe way to grow your portfolio over the years. But there's a huge advantage to picking individual stocks: Your returns can be massive and life-changing.
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
11:11am, Wednesday, 30'th Jul 2025
Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.
Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now
11:11am, Wednesday, 16'th Jul 2025
In a volatile market, low-beta picks like VIPS, ALKT, FUTU and VRNA offer investors stability with solid upside potential.
What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?
01:01pm, Tuesday, 15'th Jul 2025
Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)
05:58pm, Monday, 14'th Jul 2025
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
